Surgical Site Infection Control Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Surgical Site Infection Control Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Surgical Site Infection Control Market is expected to grow at a CAGR of 5.7% during the forecast period (2022-2027).

The Covid-19 pandemic underlined the critical necessity of hand hygiene and the use of conventional infection control methods, as the World Health Organization and the Centers for Disease Control and Prevention (CDC) recommended, in reducing the number of surgical site infections. During the Covid-19 epidemic, surgical site infection rates were reported to have decreased in healthcare settings. For instance, according to the article published in the National Library of Medicine in September 2020, by Pasquale Losurdo, during the SARS-CoV-2 lockdown, the total number of SSIs was drastically reduced, especially for superficial and deep SSIs. This may be due to a reduction in the number of surgical procedures and also due to increased focus on infection prevention with the wide usage of PPE kits and other sanitary regulations. Thus, the COVID-19 pandemic has increased the need for surgical site infection control products and may drive the growth of the market.

The increasing hospital-acquired infections and surgeries have increased and risen in the geriatric population. According to the Centers for Disease Control and Prevention, Hospital Associated Infection Progress report 2020, in the United States, there are 425 surgical site infections were observed due to open reduction of the fracture, 222 due to gall bladder surgery, 311 due to laminectomy surgery, and 496 due to cesarean section surgery. Such a high incidence of surgical site infection in the country is expected to drive the growth of the market.

Furthermore, according to the United Nations' World Ageing Population 2020 highlights, the number of people aged 65 years or above is expected to double by 2050, from 727 million in 2020 to 1.5 billion in 2050. This age group is at a higher risk for various age-related illnesses and surgical site infection, which has resulted in higher adoption of SSI control products, preventing infections among people. Thus the market will grow over the forecast period as the population ages.

Additionally, in January 2020, Becton, Dickinson, and Company launched BD PurPrep patient preoperative skin preparation with a sterile solution. It is one of the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation (PVP-I; 0.83% available iodine and 72.5% isopropyl alcohol) commercially available in the United States.

However, a lack of awareness about SSI among individuals restrained the market over the forecast period.

Key Market TrendsSuperficial Incisional Segment is Expected to Exhibit Fast Growth Rate Over the Forecast Period

Only skin and subcutaneous tissue of the incision are infected in a superficial incisional SSI. This infection occurs only in the area where the incision was made on the skin. The rate of superficial incision SSI is expected to boost the segment growth. According to the article titled "Impact of lockdown for SARS-CoV-2 (COVID-19) on surgical site infection rates: a monocentric observational cohort study" published in September 2020, in the COVID-19 era, the rate of global SSIs was 3.3%, and superficial SSIs was 0.8 %. Such a rate of superficial surgical site infection creates the need for infection control products and thus drives the growth of the market segment.

The rising incidence of hospital-acquired infections, a growing geriatric population, and subsequent growth in the prevalence of chronic diseases are expected to boost the segment as per the study titled "Healthcare-Associated Infections A New Pathology in Medical Practice?" published in February 2020, about 50% of hospital-acquired infections occur in the intensive care unit (ICU).

The outbreak of COVID-19 has significantly impacted the growth of the SSI market. The usage of superficial incisional SSI control that protects healthcare facilities and safeguards personnel performing medical procedures that expose them to the virus is rising.​ As a result, several companies have increased their production and are focusing on developing new products.

Additionally, in May 2021, Becton, Dickinson, and Company launched BD Surgiphor Sterile Wound Irrigation System, the first and only ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution that mechanically loosens and removes wound debris. Such launches are expected to propel the growth of the market.

Thus, all the factors above, such as rising surgical site infection and hospital-acquired disorders, boost the segment growth.

North America Captured the Large Market Share and is Expected to Retain its Dominance

The surgical site infection control market has been dominated by North America, with the United States accounting for the largest share of regional revenue. SSIs are the most common healthcare-associated infection (HAI) among inpatients in acute care hospitals in the United States (tied with pneumonia). According to the Center for Disease Control and Prevention, Healthcare Associated Infection Progress Report 2020, there are nearly 18,416 surgical site infections are reported in 2020 in the United States. It also reported that out of these 6.094 infection were during colon surgery and 2,173 occured during hip arthroplasty. Such high rate of surgical site infection creates the need for SSIC products and thus propells the growth of the market.

According to 2022 data by the American Health Association, there were approximately 33,356,853 hospital admissions in 2022. Many of these admissions were due to chronic diseases and critical procedures, like heart bypass surgery. Thus increasing number of hospital admissions is expected to have more SSIs, thereby boosting the market in the region.

Thus, all factors above are expected to boost the market in the region over the forecast period.

Competitive Landscape

The Surgical Site Infection Control market is moderately competitive. 3M Company, Becton, Dickinson and Company, Biomerieux SA, Getinge Group, and Johnson & Johnson are some significant players in the surgical site infection control market. The competitive rivalry of the market studied has intensified, owing to the constant product innovations worldwide.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.